Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Food Sci ; 87(9): 4203-4220, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35982642

RESUMO

Liupao tea (fermented dark tea) may improve the active function of hyperlipidemia. Utilizing a hyperlipidemia Sprague-Dawley model and UPLC-MS/MS metabolomics, we examined how the effect of Liupao and green tea extracts on hyperlipidemia and antoxidant enzyme levels and compared their constituents. The results showed that the two types of tea could reduce the levels of total cholesterol (TC), total triglyceride, and low-density lipoprotein cholesterol (LDL-C); increase the contents of bile acids and cholesterol in feces; and improve catalase and glutathione peroxidase (GSH-Px) activities. Compared with the model control group, Liupao tea effectively reduced TC and LDL-C levels by 39.53% and 58.55% and increased GSH-Px activity in the liver by 67.07%, which was better than the effect of green tea. A total of 93 compounds were identified from two samples; the amounts of alkaloids and fatty acids increased compared with green tea, and ellagic acid, hypoxanthine, and theophylline with relatively high contents in Liupao tea had a significantly positive correlation with antihyperlipidemic and antioxidant effects. Therefore, Liupao tea had better antihyperlipidemic and antioxidant activities in vivo than green tea, which might be related to the relatively high content of some active substances.


Assuntos
Hiperlipidemias , Hipolipemiantes , Antioxidantes/uso terapêutico , Ácidos e Sais Biliares , Catalase , LDL-Colesterol , Cromatografia Líquida , Ácido Elágico , Ácidos Graxos , Glutationa Peroxidase , Humanos , Hiperlipidemias/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Hipoxantinas/uso terapêutico , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Espectrometria de Massas em Tandem , Chá , Teofilina/uso terapêutico , Triglicerídeos/uso terapêutico
2.
Cancer Detect Prev ; 15(4): 327-9, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1794140

RESUMO

Amphotericin B (AMB) is a mainstay in the treatment of serious systemic fungal infections, such as those occurring prevalently in immuno-compromised patients treated with immunosuppressive agents or affected by Acquired Immunodeficiency Syndrome (AIDS). However AMB is an extremely toxic agent whose therapeutical utilization is often accompanied by acute side effects and chronic impairment of renal function. It is here reported that the preactivation of polymorphonucleated cells (PMN) in vivo, by a new immunomodulatory agent (PCF 39:N alpha-5[1,6,dihydro-(6-oxo-9 purinyl) pentoxycarbonyl]-L-Arginine) allows marked reduction of the AMB doses with full retention of therapeutic efficacy. This was observed in an experimental fungal infection induced in mice by intravenous inoculation of Candida albicans.


Assuntos
Adjuvantes Imunológicos/farmacologia , Anfotericina B/farmacologia , Arginina/análogos & derivados , Candidíase/tratamento farmacológico , Hipoxantinas/farmacologia , Neutrófilos/efeitos dos fármacos , Fagocitose/efeitos dos fármacos , Adjuvantes Imunológicos/uso terapêutico , Anfotericina B/administração & dosagem , Anfotericina B/uso terapêutico , Animais , Arginina/farmacologia , Arginina/uso terapêutico , Candidíase/complicações , Ciclofosfamida/toxicidade , Sinergismo Farmacológico , Quimioterapia Combinada , Feminino , Hipoxantinas/uso terapêutico , Hospedeiro Imunocomprometido , Síndromes de Imunodeficiência/induzido quimicamente , Síndromes de Imunodeficiência/complicações , Camundongos , Camundongos Endogâmicos BALB C/imunologia , Neutrófilos/imunologia
3.
Aviat Space Environ Med ; 55(10): 927-30, 1984 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-6093764

RESUMO

Prolonged exposure to hyperbaric oxygen causes central nervous system (CNS) oxygen toxicity manifested by grand mal seizures. The superoxide anion is believed to be a cause of tissue damage in CNS oxygen toxicity and it is proposed that xanthine oxidase activity is one of the prime sources of superoxide. Groups of mice were given equivalent doses of allopurinol, hypoxanthine, or saline, and exposed to five atmospheres absolute of oxygen. It was proposed that allopurinol, a xanthine oxidase inhibitor, would decrease the rate of superoxide formation thus delaying the onset of oxygen-induced seizures. It was further proposed that hypoxanthine would increase the rate of superoxide formation decreasing the preconvulsive latency. The data indicated that neither allopurinol nor hypoxanthine altered susceptibility to the CNS manifestations of oxygen toxicity. The results do not support the theory that xanthine oxidase is a prime source of superoxide anions in mouse brain.


Assuntos
Alopurinol/uso terapêutico , Epilepsia Tônico-Clônica/prevenção & controle , Oxigenoterapia Hiperbárica/efeitos adversos , Xantina Oxidase/antagonistas & inibidores , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Epilepsia Tônico-Clônica/etiologia , Feminino , Radicais Livres , Hipoxantinas/uso terapêutico , Masculino , Camundongos , Oxigênio/toxicidade , Superóxidos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA